Basilea Pharmaceutica AG
SIX:BSLN

Watchlist Manager
Basilea Pharmaceutica AG Logo
Basilea Pharmaceutica AG
SIX:BSLN
Watchlist
Price: 41.15 CHF -0.48%
Market Cap: 498.8m CHF
Have any thoughts about
Basilea Pharmaceutica AG?
Write Note

Basilea Pharmaceutica AG
Investor Relations

Basilea Pharmaceutica AG engages in the development and commercialization of pharmaceutical products. The company is headquartered in Basel, Basel-Stadt and currently employs 154 full-time employees. The company went IPO on 2004-03-25. The firm operates in one segment, which is the discovery, development and commercialization of innovative pharmaceutical products to meet the needs of patients with cancer and infectious diseases. The company launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of severe bacterial infections. Additionally It is conducting clinical studies with two targeted drug candidates for the treatment of a range of cancers and have a number of preclinical assets in both cancer and infectious diseases in its portfolio.

Show more

Earnings Calls

Show Transcript
Previous
Next
Loading

Management

Mr. David Veitch
Chief Executive Officer
No Bio Available
Mr. Adesh Kaul
Chief Financial Officer
No Bio Available
Dr. Gerrit Hauck Ph.D.
Chief Technology Officer
No Bio Available
Dr. Laurenz Kellenberger Ph.D.
Chief Scientific Officer
No Bio Available
Dr. Marc Engelhardt M.D.
Chief Medical Officer
No Bio Available
Dr. Peer Nils Schroder Ph.D.
Head of Corporate Communications & Investor Relations
No Bio Available
Mr. Damian Heller
General Counsel & Corporate Secretary
No Bio Available
Mr. Andreas Kumin
Head of Corporate Development
No Bio Available
Ms. Ursula Eberhardt
Head of Global Human Resources
No Bio Available
Mr. Mark Jones Ph.D.
Head of Global Affairs
No Bio Available

Contacts

Address
BASEL-STADT
Basel
Grenzacherstrasse 487
Contacts
+41616061111.0
www.basilea.com